证券代码：600055 证券简称：万东医疗 公告编号：2026-010 北京万东医疗科技股份有限公司 关于公司及子公司使用闲置募集资金 及自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 产品种类：银行理财 本次现金管理总额：募集资金 1 亿元、自有资金 2.1 亿元 履行的审议程序：2025年 3月 20日召开的第十届董事会第六次会议、 第十届监事会第六次会议及 2025 年 4 月 16 日召开的 2024 年年度股东大会 审议批准《关于使用部分暂时闲置募集资金及自有资金进行现金管理的议 案》。 一、情况概述 （一）现金管理目的 北京万东医疗科技股份有限公司（以下简称"公司"）及子公司为提 高募集资金和自有资金效率，合理利用部分闲置募集资金及自有资金，在 确保不影响募集资金项目建设和使用、募集资金和自有资金安全的情况下， 增加公司的收益，为公司及股东获取更多回报。 （二）现金管理金额 本次现金管理总金额为：公司使用募集资金 1 亿元,自有资金 1 亿元； 子公司使用自有资金 1.1 亿元 ...

Core Viewpoint - The company plans to repurchase shares through centralized bidding, with a total amount between 30 million to 60 million yuan, at a price not exceeding 25 yuan per share, with the implementation period until August 21, 2026 [1] Summary by Relevant Sections - **Share Repurchase Plan**: The company has announced a share repurchase plan set to begin on August 22, 2025, with a budget of 30 million to 60 million yuan, and a maximum purchase price of 25 yuan per share [1] - **Implementation Timeline**: The repurchase will be executed until August 21, 2026 [1] - **Current Repurchase Status**: As of the end of January 2026, the company has repurchased a total of 1.8027 million shares, representing 0.2564% of the total share capital, with a total expenditure of approximately 29.9928 million yuan, at prices ranging from 15.71 yuan to 17.99 yuan per share [1] - **Unexecuted Repurchase**: No repurchase was executed in January 2026 [1]

Core Viewpoint - WanDong Medical (600055) expects a net profit loss of approximately 199 million to 257 million yuan for the fiscal year 2025, with a net profit loss excluding non-recurring gains and losses estimated at 213 million to 271 million yuan [1] Group 1: Financial Performance - The company has adjusted its marketing strategy to adapt to market changes, successfully winning imaging equipment projects with more competitive pricing, which has impacted gross margins and compressed net profit margins [1] - The anticipated losses for 2025 reflect the challenges faced in maintaining profitability amid strategic shifts and market conditions [1] Group 2: Strategic Initiatives - The company is increasing its R&D investment and actively expanding into overseas markets while strengthening marketing efforts in high-grade domestic hospitals, contributing to its strategic transformation towards high-end and international markets [1] - To address structural challenges in the industry, the company is hiring specialized R&D personnel and enhancing its comprehensive layout in high-end medical imaging equipment, particularly in CT, MR, and DSA categories [1] Group 3: Technological Development - The company focuses on the R&D of core components and high-performance equipment, establishing a technology reserve framework of "research generation, reserve generation, and development generation" [1] - Efforts to deepen overseas market penetration include improving the overseas marketing organizational structure and functions, implementing overseas station expansions, and building regional service centers to enhance medical accessibility [1]

Group 1 - The core viewpoint of the news is that Wandong Medical is expected to report significant losses in 2025, transitioning from profit to loss due to various operational challenges [1][3]. Group 2 - As of January 30, 2026, Wandong Medical's stock closed at 15.94 yuan, with a trading volume of 59,200 shares and a total transaction amount of 94.49 million yuan [1]. - On January 30, the net inflow of main funds was 272,500 yuan, accounting for 0.29% of the total transaction amount, while retail investors saw a net outflow of 287,290 yuan, representing 3.04% of the total [1][3]. Group 3 - Wandong Medical forecasts a net profit loss of between 199.73 million yuan and 257.83 million yuan for the year 2025, with a non-recurring net profit loss expected to be between 213.23 million yuan and 271.33 million yuan [1][3]. - The company attributes the expected losses to participation in centralized procurement of medical devices, adjustments in pricing strategies affecting gross margins, and increased investments in research and development as well as expansion into overseas and high-end markets [1][3].

Core Viewpoint - WanDong Medical (600055) is facing a significant financial downturn, with projected net losses for 2025, primarily due to increased competition and strategic investments in R&D and international markets [1][3]. Financial Performance - WanDong Medical anticipates a net profit loss of between 199 million to 257 million yuan for the year 2025, marking a shift from profit to loss compared to the previous year [1][3]. - The expected loss in net profit is attributed to participation in medical device procurement, which has led to a decrease in gross margin, alongside increased investments in research and development and overseas market expansion [1]. Company Announcements - On January 26, 2026, WanDong Medical held its 13th meeting of the 10th Board of Directors, where Wang Jianguo was elected as the new chairman, succeeding Ma Chibing, who resigned for personal reasons [1][2]. - The first extraordinary general meeting of shareholders in 2026 was also held on January 26, where Wang Jianguo was elected as a non-independent director with 98.3021% of the votes in favor [2]. - The Board's strategic committee has been adjusted to include Wang Jianguo, Song Jinsong, Zhong Zheng, and Liu Xiao, with Wang Jianguo serving as the convener [2].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 经财务部门初步测算，预计2025年度实现归属于母公司所有者的净利润为-19,873万元到-25,683万元， 与上年同期相比，将出现亏损。 预计2025年度实现归属于母公司所有者的扣除非经常性损益后的净利润为-21,323万元到-27,133万元， 与上年同期相比，将出现亏损。 （三）本期业绩预告数据未经会计师事务所审计。 二、上年同期经营业绩和财务状况 （一）公司2024年度利润总额为16,686万元，归属于母公司所有者的净利润为15,735万元，归属于母公 司所有者的扣除非经常性损益的净利润为14,242万元。 ● 业绩预告的具体适用情形：净利润为负值。 ● 北京万东医疗科技股份有限公司（以下简称"公司"）预计2025年度实现归属于母公司所有者的净利润 为-19,873万元到-25,683万元。预计2025年度实现归属于母公司所有者的扣除非经常性损益 ...

市净率(LF)历史分位(%) 100 ହ୍ର ୨୦ 80 79 70 60 50 4745 4763 40 31o34 30 27-43 20 18:41 1643 10 7-01 0- 2020-12-37 1 2021-06-30 ' 2021-12-37 ' 2-12-37 3-12-37 2n- 公司 -○- 行业均值 制图数据来自恒生聚源数据库 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 历年净利、扣非同比增长情况(%) 100 – ଚ୍ଚ 50 30.66 7.51 0 -4:27 -16.98 16.54 -50 - -100 -150 -200 -250 244.76 -300 2021 2022 2023 2020 2024 2025E →○- 归母净利润同比增长率 -○- 扣非净利润同比增长率 制图数据来自恒生聚源数据库 净利、扣非季度变动情况(亿元) 1 20.5 0.684 ).33-0.51 0.3 2.41 0.354 1.163 0 0.44 -0.78 -0.5 -1 -2.0( -1.5 -2 -2.5 扣非净利润 归母净利润 制图数据来自恒生聚源数据库 ...

2025年度，公司持续加大研发投入，同时积极拓展海外市场并强化国内高等级医院的营销力度，助力公 司向大放、向高端、向海外的战略转型，但也导致净利润承压。面对行业结构性升级挑战，公司引进专 业研发技术人员，深化高端医学影像设备的全面布局，尤其是大放品类的CT、MR和DSA。公司聚焦核 心零部件及高性能设备研发，构建"研究一代、储备一代、开发一代"的技术储备格局。同时，公司加速 海外市场的覆盖和深耕，持续完善海外营销组织架构和职能体系，通过实施海外驻点扩容、构建地域性 服务中心等举措，有助提升"一带一路"国家和地区的医疗可及性。 证券之星消息，万东医疗发布业绩预告，预计2025年全年归属净利润亏损1.99亿元至2.57亿元。 公告中解释本次业绩变动的原因为： 2025年度，公司深度参与医疗设备集中采购，为适应市场变化，适时优化了营销策略，通过更具竞争力 的价格方案成功中标影像设备项目，价格调整对毛利率产生了一定影响，导致净利润空间有所压缩。 万东医疗2025年三季报显示，前三季度公司主营收入11.89亿元，同比上升8.73%；归母净利润-2720.98 万元，同比下降123.51%；扣非净利润-4457.54万元 ...

格隆汇1月30日丨万东医疗(600055.SH)公布，经财务部门初步测算，预计2025年度实现归属于母公司所 有者的净利润为-19,873万元到-25,683万元，与上年同期相比，将出现亏损。预计2025年度实现归属于 母公司所有者的扣除非经常性损益后的净利润为-21,323万元到-27,133万元，与上年同期相比，将出现 亏损。 ...

万东医疗表示，2025年，公司深度参与医疗设备集中采购，为适应市场变化，适时优化了营销策略，通 过更具竞争力的价格方案成功中标影像设备项目，价格调整对毛利率产生了一定影响，导致净利润空间 有所压缩。 北京商报讯（记者 丁宁）1月30日晚间，万东医疗（600055）发布2025年业绩预告显示，公司预计2025 年实现归属净利润为-1.99亿元到-2.57亿元。 ...